Zai Lab’s Oncology SAB Sales Trigger

🚀 Battle Card: Zai Lab Limited

• Lieping Chen, M.D., Ph.D., United Technologies Corp Chair in Cancer Research, Yale University School of Medicine · 🔗 LinkedIn

• Richard S. Finn, M.D., Director, Signal Transduction Program, UCLA Jonsson Comprehensive Cancer Center · 🔗 LinkedIn

• Thomas F. Gajewski, M.D., Ph.D., Director, Melanoma Oncology Clinic & Immunology and Cancer Program, Univ. of Chicago · 🔗 LinkedIn

• Melissa L. Johnson, M.D., Director, Lung Cancer Research, Sarah Cannon Research Institute · 🔗 LinkedIn

• Matthew Krebs, M.D., Ph.D., Senior Lecturer, Experimental Cancer Medicine & Early Phase Trials Lead, Univ. of Manchester · 🔗 LinkedIn

• Patricia LoRusso, M.D., D.O., Director, Early Phase Clinical Trials & Associate Center Director, Yale Cancer Center · 🔗 LinkedIn

• Michael T. Lotze, M.D., FACS, Professor & Director, DAMP Laboratories, UPMC Hillman Cancer Center · 🔗 LinkedIn

• Timothy Yap, M.B.B.S., Ph.D., FRCP, Medical Oncologist & Professor, MD Anderson Cancer Center · 🔗 LinkedIn

• Forming a world-class Oncology SAB accelerates pipeline validation and de-risks trials → Source

• This Zai Lab Limited sales trigger signals urgent demand for expert-management platforms.

• Lack of centralized SAB management for seamless expert collaboration

• Slow insight delivery from advisory feedback to R&D decisions

• Primary: Advisory Board Management Software → Streamlined expert coordination & faster strategic decisions

• Expansion: Real-time Clinical Data Analytics → Immediate actionable insights across oncology portfolio

• HQ: Shanghai, China & Cambridge, MA

• Employees: ≈ 600

• Rev: ≈ $180 M

• Website: zailaboratory.com

🤼 Competitive Intel

• Veeva Systems — SAB Management / MRS
• Unique edge: Integrated medical CRM + advisory modules
• Evaluated by R&D for workflow integration

• Medidata Solutions — Clinical & Advisory Data
• Unique edge: End-to-end trial data platform
• Evaluated by Clinical Ops for data consistency

• GLG — Expert Network
• Unique edge: Fast access to KOLs
• Evaluated by Medical Affairs for depth of network

• IQVIA — Consulting & Analytics
• Unique edge: Cross-functional market & clinical insights
• Evaluated by Strategy leads for global footprint

• Clarivate — Scientific Advisory Services
• Unique edge: Bibliometrics & KOL mapping
• Evaluated by Business Dev for thought-leadership analysis

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑❑
PROOF_METRIC  = ❑❑
CTA_STYLE     = ❑❑
TONE          = ❑❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = ≈ TBD
COMPANY     = Zai Lab Limited
DEPT        = Oncology
SIZE        = 8
BOTTLENECK  = lack of centralized SAB management
EVENT       = Establishes Oncology Scientific Advisory Board
DETAIL      = formation of advisory board of world-class leaders
PAIN        = slow insight delivery from advisory feedback to R&D decisions
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250813280130&div=41152219
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈ 600
REV_EST     = ≈ $180M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: 8-person Oncology

≈ TBD—noticed your Oncology team is ≈ 8.

That’s when lack of centralized SAB management slows growth.

We helped ≈ TBD fix this with ❑❑.

Result: ≈ TBD.  
Want the 2-min recap?

PS—next bottleneck hits ≈ ≈ TBD.

DM ≤45 words, TONE:
Saw your post about formation of advisory board of world-class leaders — slow insight delivery from advisory feedback to R&D decisions.  
❑❑. ❑❑.  
Send case study?